PubAg

Main content area

Making Targeted Therapy Compatible with Checkpoint Immunotherapy

Author:
Fernández, Ariel
Source:
Trends in biotechnology 2017
ISSN:
0167-7799
Subject:
T-lymphocytes, antibodies, cross reaction, immunotherapy, mutation, neoplasms
Abstract:
Immune checkpoint blockades induced by antibodies are revolutionizing cancer therapy., Combinations of checkpoint immunotherapies with kinase inhibitors (KIs) are being clinically evaluated as oncogenic mutations arise. Off-target KI cross-reactivity will often compromise synergistic efficacy, with KIs suppressing T cell functionalities that checkpoint blockers are purportedly boosting. This incompatibility may be removed through molecular optimization.
Agid:
5638387